The Role of Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer

Neeraj Agarwal, MD, and Simon Chowdhury, MD, examine the efficacy and safety data presented in the recent publication, “Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.”

Drs Agarwal and Chowdhury analyze the survival data from the phase 3 TITAN study of apalutamide in men with mCSPC.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.

GU oncologists discuss toxicities from androgen deprivation therapy and apalutamide as reported in the phase 3 TITAN study.

Genitourinary oncology experts share key takeaways and considerations for treating patients with metastatic castration-sensitive prostate cancer.

Drs Agarwal and Chowdhury discuss future directions for mCSPC, including potential use of triplet combination therapy.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.